Rockville-based biotech company MacroGenics filed for a $60 million initial public offering on Sept. 4.
MacroGenics, a clinical-stage biotech focused on oncology, said it would use the proceeds to fund clinical development for margetuximab (also known as MGAH22) — currently in mid-stage trials for metastatic breast cancer and gastroesophageal cancer — and a second product, MGA271. Both are monoclonal antibodies. The cash from the IPO would also go toward advancing MacroGenics’ early-stage pipeline.
In August, another Maryland-based biotech firm, Intrexon Corp., filed for an initial public offering, and raised $160 million in the process.-30-
Baltimore biotech company PathSensors will be acquired
AsclepiX Therapeutics eyeing clinical trials after closing $35M Series A
Venture capital firm Catalio Capital Management spins out of Camden Partners
College Park’s Immuta and IonQ both raised millions in new VC funding
Sign-up for daily news updates from Technical.ly Baltimore